Plant-Based Investment Corp. (“PBIC”, or the “Company”) (CSE:PBIC), announces that the Company has acquired 3,333,333 units (the “Units”) of Aion Therapeutic Inc. (“AION”) (CSE:AION) at a price of $0.075 per Unit for a total subscription amount of approximately $250,000 through a non-brokered private placement (the “Offering”). Each Unit is comprised of one common share of AION (“Common Share”) and one-half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the Company to acquire one Common Share until February 22, 2023 at a price of $0.15 per Common Share, provided that AION has the right to accelerate the expiry date of the Warrants to thirty days following written notice to the Company if the closing market price of the Common Shares on the Canadian Securities Exchange is at or above $0.20 per Common Share for a period of ten consecutive trading days

Prior to the completion of the Offering, the Company held 11,000,000 Common Shares and 5,000,000 Warrants of AION, representing approximately 8.81% of the issued and outstanding Common Shares of AION on a non-diluted basis and approximately 12.33% of the issued and outstanding Common Shares of AION on a partially diluted basis, assuming the exercise of all of the Warrants held by the Company.


Following the completion of the Offering, the Company beneficially owns or controls 14,333,333 Common Shares and 6,666,667 Warrants of AION, representing approximately 11.48% of the issued and outstanding Common Shares of AION on a non-diluted basis and approximately 15.63% of the issued and outstanding Common Shares of AION on a partially diluted basis, assuming the exercise of all of the Warrants held by the Company.

The Common Shares and Warrants of AION were acquired for investment purposes. While Company currently has no plans or intentions with respect to the Common Shares and Warrants of AION, the Company may from time to time acquire additional securities of AION, may sell all or a portion of its securities of AION or may continue to hold the Common Shares and Warrants of AION, or other securities of AION, depending on market conditions, the Company’s view of AION’s prospects, other investment opportunities and other factors considered relevant to the Company.

This news release is being issued in accordance with National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues in connection with the filing of an early warning report of the Company dated February 22, 2021. A copy of the early warning report will be available on AION’s issuer profile on SEDAR at www.sedar.com.

For further information, please contact:

Plant-Based Investment Corp.
240 Richmond Street West
Toronto, ON, M5V1V6
Attention: Paul Crath, Chief Executive Officer
Tel: (647) 660-0566

SOURCE: Plant-Based Investment Corp.

View source version on accesswire.com:
https://www.accesswire.com/631199/PBIC-Announces-Investment-in-Aion-Therapeutic-Inc

News Provided by ACCESSWIRE via QuoteMedia

American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less